Phase II trial of piperazinedione in metastatic sarcoma

Academic Article

Abstract

  • Thirty-five patients with metastatic sarcomas received piperazinedione 9 mg/m2 every 3 weeks. Of 27 evaluable patients, 3 patients had stable disease for at least 6 weeks. The dose-limiting toxicity was myelosuppression. Piperazinedione is inactive in patients with drug-resistant metastatic sarcomas.
  • Author List

  • Presant CA; Bartolucci AA
  • Start Page

  • 185
  • End Page

  • 187
  • Volume

  • 5
  • Issue

  • 2